The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 Størset E +5 more
europepmc +1 more source
Pharmacological approach to personalize the use of anti-cancer drugs [PDF]
, 2013 Graan, Anne-joy
core +2 more sources
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. [PDF]
Br J Clin Pharmacol, 2016 Vanhove T +5 more
europepmc +1 more source
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 Vanhove T +4 more
europepmc +1 more source
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. [PDF]
Br J Clin Pharmacol, 2015 de Graan AJ +8 more
europepmc +1 more source
4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. [PDF]
Clin Transl Sci, 2017 Wollmann BM +6 more
europepmc +1 more source
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? [PDF]
Br J Clin Pharmacol, 2016 Gjestad C +3 more
europepmc +1 more source
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers [PDF]
A Galetin +21 more
core +1 more source
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. [PDF]
Intern Med, 2018 Hirayama T +7 more
europepmc +1 more source
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. [PDF]
Br J Clin Pharmacol, 2014 Kasichayanula S +8 more
europepmc +1 more source